vs
百时美施贵宝（BMY）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
RYDER SYSTEM INC的季度营收约是百时美施贵宝的1.0倍（$13.1B vs $12.5B），百时美施贵宝净利率更高（8.7% vs 0.7%，领先8.0%），百时美施贵宝同比增速更快（1.3% vs 1.0%），百时美施贵宝自由现金流更多（$1.6B vs $273.0M），过去两年RYDER SYSTEM INC的营收复合增速更高（102.9% vs 2.6%）
百时美施贵宝是总部位于美国新泽西州普林斯顿的跨国制药企业，核心产品覆盖多个治疗领域：包括用于心房颤动治疗的艾乐妥（阿哌沙班）、抗癌药物欧狄沃（纳武利尤单抗）、治疗多发性骨髓瘤的瑞复美（来那度胺），以及用于类风湿性关节炎等自身免疫疾病的恩瑞舒（阿巴西普）。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
BMY vs R — 直观对比
营收规模更大
R
是对方的1.0倍
$12.5B
营收增速更快
BMY
高出0.3%
1.0%
净利率更高
BMY
高出8.0%
0.7%
自由现金流更多
BMY
多$1.3B
$273.0M
两年增速更快
R
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $12.5B | $13.1B |
| 净利润 | $1.1B | $93.0M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 11.8% | — |
| 净利率 | 8.7% | 0.7% |
| 营收同比 | 1.3% | 1.0% |
| 净利润同比 | 1409.7% | -5.1% |
| 每股收益（稀释后） | $0.54 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMYR
| Q1 26 | — | $13.1B | ||
| Q4 25 | $12.5B | $3.2B | ||
| Q3 25 | $12.2B | $3.2B | ||
| Q2 25 | $12.3B | $3.2B | ||
| Q1 25 | $11.2B | $3.1B | ||
| Q4 24 | $12.3B | $3.2B | ||
| Q3 24 | $11.9B | $3.2B | ||
| Q2 24 | $12.2B | $3.2B |
净利润BMYR
| Q1 26 | — | $93.0M | ||
| Q4 25 | $1.1B | $132.0M | ||
| Q3 25 | $2.2B | $138.0M | ||
| Q2 25 | $1.3B | $131.0M | ||
| Q1 25 | $2.5B | $98.0M | ||
| Q4 24 | $72.0M | $135.0M | ||
| Q3 24 | $1.2B | $142.0M | ||
| Q2 24 | $1.7B | $127.0M |
毛利率BMYR
| Q1 26 | — | — | ||
| Q4 25 | 67.2% | — | ||
| Q3 25 | 71.9% | — | ||
| Q2 25 | 72.5% | — | ||
| Q1 25 | 72.9% | — | ||
| Q4 24 | 61.0% | — | ||
| Q3 24 | 75.1% | — | ||
| Q2 24 | 73.2% | — |
营业利润率BMYR
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 5.6% | ||
| Q3 25 | 25.5% | 6.0% | ||
| Q2 25 | 14.5% | 5.8% | ||
| Q1 25 | 26.5% | 4.3% | ||
| Q4 24 | 1.4% | 5.7% | ||
| Q3 24 | 14.1% | 5.9% | ||
| Q2 24 | 10.5% | 5.6% |
净利率BMYR
| Q1 26 | — | 0.7% | ||
| Q4 25 | 8.7% | 4.2% | ||
| Q3 25 | 18.0% | 4.4% | ||
| Q2 25 | 10.7% | 4.1% | ||
| Q1 25 | 21.9% | 3.1% | ||
| Q4 24 | 0.6% | 4.2% | ||
| Q3 24 | 10.2% | 4.5% | ||
| Q2 24 | 13.8% | 4.0% |
每股收益（稀释后）BMYR
| Q1 26 | — | $2.34 | ||
| Q4 25 | $0.54 | $3.22 | ||
| Q3 25 | $1.08 | $3.32 | ||
| Q2 25 | $0.64 | $3.13 | ||
| Q1 25 | $1.20 | $2.27 | ||
| Q4 24 | $0.05 | $3.09 | ||
| Q3 24 | $0.60 | $3.24 | ||
| Q2 24 | $0.83 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.2B | $182.0M |
| 总债务越低越好 | $44.8B | — |
| 股东权益账面价值 | $18.5B | $2.9B |
| 总资产 | $90.0B | — |
| 负债/权益比越低杠杆越低 | 2.43× | — |
8季度趋势，按日历期对齐
现金及短期投资BMYR
| Q1 26 | — | $182.0M | ||
| Q4 25 | $10.2B | $198.0M | ||
| Q3 25 | $15.7B | $189.0M | ||
| Q2 25 | $12.6B | $180.0M | ||
| Q1 25 | $10.9B | $151.0M | ||
| Q4 24 | $10.3B | $154.0M | ||
| Q3 24 | $7.9B | $162.0M | ||
| Q2 24 | $6.3B | $164.0M |
总债务BMYR
| Q1 26 | — | — | ||
| Q4 25 | $44.8B | $6.8B | ||
| Q3 25 | $48.7B | $7.3B | ||
| Q2 25 | $48.9B | $7.0B | ||
| Q1 25 | $49.5B | $6.7B | ||
| Q4 24 | $49.4B | $6.7B | ||
| Q3 24 | $49.5B | $6.6B | ||
| Q2 24 | $52.0B | $6.5B |
股东权益BMYR
| Q1 26 | — | $2.9B | ||
| Q4 25 | $18.5B | $3.1B | ||
| Q3 25 | $18.6B | $3.1B | ||
| Q2 25 | $17.4B | $3.1B | ||
| Q1 25 | $17.4B | $3.0B | ||
| Q4 24 | $16.3B | $3.1B | ||
| Q3 24 | $17.1B | $3.1B | ||
| Q2 24 | $17.0B | $3.1B |
总资产BMYR
| Q1 26 | — | — | ||
| Q4 25 | $90.0B | $16.4B | ||
| Q3 25 | $96.9B | $16.5B | ||
| Q2 25 | $94.7B | $16.5B | ||
| Q1 25 | $92.4B | $16.4B | ||
| Q4 24 | $92.6B | $16.7B | ||
| Q3 24 | $93.7B | $16.5B | ||
| Q2 24 | $94.6B | $16.4B |
负债/权益比BMYR
| Q1 26 | — | — | ||
| Q4 25 | 2.43× | 2.24× | ||
| Q3 25 | 2.63× | 2.35× | ||
| Q2 25 | 2.81× | 2.27× | ||
| Q1 25 | 2.85× | 2.21× | ||
| Q4 24 | 3.03× | 2.14× | ||
| Q3 24 | 2.89× | 2.17× | ||
| Q2 24 | 3.05× | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0B | $583.0M |
| 自由现金流经营现金流 - 资本支出 | $1.6B | $273.0M |
| 自由现金流率自由现金流/营收 | 12.8% | 2.1% |
| 资本支出强度资本支出/营收 | 3.0% | 3.3% |
| 现金转化率经营现金流/净利润 | 1.82× | 6.27× |
| 过去12个月自由现金流最近4个季度 | $12.8B | $595.0M |
8季度趋势，按日历期对齐
经营现金流BMYR
| Q1 26 | — | $583.0M | ||
| Q4 25 | $2.0B | $749.0M | ||
| Q3 25 | $6.3B | $442.0M | ||
| Q2 25 | $3.9B | $752.0M | ||
| Q1 25 | $2.0B | $651.0M | ||
| Q4 24 | $4.4B | $558.0M | ||
| Q3 24 | $5.6B | $629.0M | ||
| Q2 24 | $2.3B | $552.0M |
自由现金流BMYR
| Q1 26 | — | $273.0M | ||
| Q4 25 | $1.6B | $344.0M | ||
| Q3 25 | $6.0B | $-85.0M | ||
| Q2 25 | $3.6B | $63.0M | ||
| Q1 25 | $1.7B | $137.0M | ||
| Q4 24 | $4.1B | $-201.0M | ||
| Q3 24 | $5.3B | $30.0M | ||
| Q2 24 | $2.1B | $-87.0M |
自由现金流率BMYR
| Q1 26 | — | 2.1% | ||
| Q4 25 | 12.8% | 10.8% | ||
| Q3 25 | 49.0% | -2.7% | ||
| Q2 25 | 29.0% | 2.0% | ||
| Q1 25 | 15.1% | 4.4% | ||
| Q4 24 | 32.9% | -6.3% | ||
| Q3 24 | 44.3% | 0.9% | ||
| Q2 24 | 16.9% | -2.7% |
资本支出强度BMYR
| Q1 26 | — | 3.3% | ||
| Q4 25 | 3.0% | 12.8% | ||
| Q3 25 | 2.6% | 16.6% | ||
| Q2 25 | 2.9% | 21.6% | ||
| Q1 25 | 2.3% | 16.4% | ||
| Q4 24 | 3.1% | 23.8% | ||
| Q3 24 | 2.7% | 18.9% | ||
| Q2 24 | 2.1% | 20.1% |
现金转化率BMYR
| Q1 26 | — | 6.27× | ||
| Q4 25 | 1.82× | 5.67× | ||
| Q3 25 | 2.87× | 3.20× | ||
| Q2 25 | 2.99× | 5.74× | ||
| Q1 25 | 0.80× | 6.64× | ||
| Q4 24 | 61.65× | 4.13× | ||
| Q3 24 | 4.62× | 4.43× | ||
| Q2 24 | 1.38× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMY
| Net Product Sales | $12.1B | 97% |
| Zeposia | $159.0M | 1% |
| Opdivo Ovantig | $132.0M | 1% |
| Abecma | $100.0M | 1% |
| Sotyktu | $86.0M | 1% |
R
暂无分部数据
